Recent advances in the management of skin and soft tissue infections.

IF 4.5 3区 医学 Q2 INFECTIOUS DISEASES
Current Opinion in Infectious Diseases Pub Date : 2026-04-01 Epub Date: 2025-11-27 DOI:10.1097/QCO.0000000000001164
Asimina Valsamaki, Konstantinos Mantzarlis, George Dimopoulos
{"title":"Recent advances in the management of skin and soft tissue infections.","authors":"Asimina Valsamaki, Konstantinos Mantzarlis, George Dimopoulos","doi":"10.1097/QCO.0000000000001164","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Skin and soft tissue infections (SSTIs) are one of the most frequent infections that need management either in outpatient setting or as inpatient. The present review of the literature will present recent developments in the diagnosis and treatment of SSTIs.</p><p><strong>Recent findings: </strong>Regarding SSTIs diagnosis, point of care ultrasound (POCUS), PCR, MALDI-TOF mass spectroscopy, along with the usage of novel biomarkers, such as procalcitonin, can help in the accurate and timely diagnosis of SSTIs in a cost-effective manner. Artificial intelligence applications may be the next step in the field. In terms of treatment, the use of newly approved antibiotics, such as oritavalcin and dalbavancin, in combination with innovative methods of their delivery based on nanotechnology applications, can offer targeted and localized action, minimizing the antibiotics' microbial inhibition concentration.</p><p><strong>Summary: </strong>Even if SSTIs remain a difficult condition to treat, causing significant morbidity, mortality and economic burden on healthcare systems, ongoing scientific research is attempting to improve both diagnostic methods and treatment. More developments are expected in the near future in the areas of innovative diagnostic techniques, innovative drugs, nanotechnology applications, and antigen-based therapies.</p>","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"122-127"},"PeriodicalIF":4.5000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QCO.0000000000001164","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: Skin and soft tissue infections (SSTIs) are one of the most frequent infections that need management either in outpatient setting or as inpatient. The present review of the literature will present recent developments in the diagnosis and treatment of SSTIs.

Recent findings: Regarding SSTIs diagnosis, point of care ultrasound (POCUS), PCR, MALDI-TOF mass spectroscopy, along with the usage of novel biomarkers, such as procalcitonin, can help in the accurate and timely diagnosis of SSTIs in a cost-effective manner. Artificial intelligence applications may be the next step in the field. In terms of treatment, the use of newly approved antibiotics, such as oritavalcin and dalbavancin, in combination with innovative methods of their delivery based on nanotechnology applications, can offer targeted and localized action, minimizing the antibiotics' microbial inhibition concentration.

Summary: Even if SSTIs remain a difficult condition to treat, causing significant morbidity, mortality and economic burden on healthcare systems, ongoing scientific research is attempting to improve both diagnostic methods and treatment. More developments are expected in the near future in the areas of innovative diagnostic techniques, innovative drugs, nanotechnology applications, and antigen-based therapies.

皮肤和软组织感染治疗的最新进展。
综述目的:皮肤和软组织感染(SSTIs)是最常见的感染之一,需要在门诊或住院治疗。目前的文献综述将介绍性传播感染诊断和治疗的最新进展。最新发现:对于SSTIs的诊断,护理点超声(POCUS), PCR, MALDI-TOF质谱,以及使用新的生物标志物,如降钙素原,可以帮助SSTIs以经济有效的方式准确和及时地诊断。人工智能应用可能是该领域的下一步。在治疗方面,使用新批准的抗生素,如奥利他霉素和达巴伐辛,结合基于纳米技术应用的创新给药方法,可以提供靶向和局部作用,最大限度地降低抗生素的微生物抑制浓度。摘要:即使性传播感染仍然是一种难以治疗的疾病,造成严重的发病率、死亡率和卫生保健系统的经济负担,正在进行的科学研究正在试图改进诊断方法和治疗方法。预计在不久的将来,在创新诊断技术、创新药物、纳米技术应用和基于抗原的治疗等领域将有更多的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.70
自引率
2.60%
发文量
121
审稿时长
6-12 weeks
期刊介绍: This reader-friendly, bimonthly resource provides a powerful, broad-based perspective on the most important advances from throughout the world literature. Featuring renowned guest editors and focusing exclusively on two topics, every issue of Current Opinion in Infectious Disease delivers unvarnished, expert assessments of developments from the previous year. Insightful editorials and on-the-mark invited reviews cover key subjects such as HIV infection and AIDS; skin and soft tissue infections; respiratory infections; paediatric and neonatal infections; gastrointestinal infections; tropical and travel-associated diseases; and antimicrobial agents.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书